Rigel Pharmaceuticals Inc (RIGL) — 10-Q Filings
All 10-Q filings from Rigel Pharmaceuticals Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Rigel's Q3 Net Income Soars 125% on Strong Product Sales
— Nov 4, 2025 Risk: medium
Rigel Pharmaceuticals Inc. reported a significant increase in net income to $27.9 million for the three months ended September 30, 2025, up from $12.4 million i -
Rigel Navigates Commercial Adjustments Amidst Equity Shifts
— Aug 5, 2025 Risk: medium
RIGEL PHARMACEUTICALS INC reported a net loss for the six months ended June 30, 2025, though specific dollar amounts for revenue and net income were not provide -
Rigel Pharmaceuticals Files Q1 2025 10-Q
— May 6, 2025 Risk: medium
Rigel Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first q -
Rigel Pharmaceuticals Q3 2024: Revenue Details
— Nov 7, 2024 Risk: medium
Rigel Pharmaceuticals Inc. reported its third-quarter 2024 results, with net product revenues for the nine months ended September 30, 2024, totaling $70.6 milli -
Rigel Pharmaceuticals Reports Q2 2024 Financials
— Aug 6, 2024 Risk: medium
Rigel Pharmaceuticals Inc. filed its 10-Q for the period ending June 30, 2024. The company reported net sales of $17.534 million for the six months ended June 3 -
Rigel Pharmaceuticals Files 10-Q for Period Ending March 31, 2024
— May 7, 2024 Risk: medium
RIGEL PHARMACEUTICALS INC (RIGL) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Rigel Pharmaceuticals Inc. filed a 10-Q for the period ending Marc
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX